SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001370368-22-000059
Filing Date
2022-07-19
Accepted
2022-07-19 06:49:12
Documents
60
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 6-K nvs-20220630.htm   iXBRL 6-K 13065
7 99.1 FINANCIAL REPORT Q2 2022 nvs-20220630-99_1.htm EX-99 308817
8 99.2 INTERIM FINANCIAL REPORT nvs-20220630-99_2.htm   iXBRL EX-99 4519151
9 IMAGE logo.jpg GRAPHIC 26773
10 IMAGE coverifr.jpg GRAPHIC 409858
  Complete submission text file 0001370368-22-000059.txt   18316190

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nvs-20220630_cal.xml EX-101.CAL 74011
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nvs-20220630_def.xml EX-101.DEF 437469
4 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT nvs-20220630_lab.xml EX-101.LAB 1846405
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nvs-20220630_pre.xml EX-101.PRE 445503
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nvs-20220630.xsd EX-101.SCH 524176
54 EXTRACTED XBRL INSTANCE DOCUMENT nvs-20220630_htm.xml XML 3953094
Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Filer) CIK: 0001114448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-15024 | Film No.: 221090309
SIC: 2834 Pharmaceutical Preparations